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Abstract
To begin to unravel the complexity of HIV-associated changes in the brain, broader, multifaceted
analyses of cerebrospinal fluid (CSF) are needed that examine a wide range of proteins reflecting
different functions. CSF from HIV-infected patients with a range of cognitive deficits was
compared to CSF from uninfected, cognitively normal patients to begin to identify protein changes
associated with HIV infection and neurological disease progression. Uninfected patients showed
relatively consistent patterns of protein expression. Highly expressed proteins in CSF included
monocyte chemotactic protein-1, tissue inhibitors of metalloproteases, granulocyte colony-
stimulating factor, adiponectin, soluble tumor necrosis factor receptor-1, urokinase-type
plasminogen activator receptor, and insulin-like growth factor binding protein-2. Inflammatory
and anti-inflammatory cytokines were expressed at low levels. HIV-infected patients showed
increases in inflammatory proteins (interferon-gamma, tumor necrosis factor-alpha), anti-
inflammatory proteins (IL-13), and chemokines but these correlated poorly with neurological
status. The strongest correlation with increasing severity of neurological disease was a decline in
growth factors, particularly, brain-derived neurotrophic factor and NT-3. These studies illustrate
that HIV infection is associated with parallel changes in both inflammatory and neuroprotective
proteins in the CSF. The inverse relationship between growth factors and neurological disease
severity suggests that a loss of growth factor neuroprotection may contribute to the development
of neural damage and may provide useful markers of disease progression.
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Introduction
Early in the course of HIV-1 infection, monocytes are thought to carry the virus into the
central nervous system thereby initiating infection, inflammation, and progressive neural
dysfunction (Koenig et al. 1986; Kolson 2002; Bouwman et al. 1998; Towfighi et al. 2004;
Hult et al. 2008). The neural dysfunction may be due, in part, to the accumulation of
macrophage- and microglia-derived toxins (Epstein and Gendelman 1993; Zheng and
Gendelman 1997; Giulian and Noonan 1998; Xiong et al. 2000). Many studies have
attempted to define the toxic factors in the cerebrospinal fluid (CSF) that correlate with
disease progression in an effort to identify individuals at highest risk for neurological
disease and provide clues to the processes that lead to neuronal dysfunction. These studies
have identified a number of known proteins thought to reflect inflammatory activity
(Perrella et al. 1992; Elovaara and Muller 1993; Achim et al. 1993; Cinque et al. 1998,
2004; Conant et al. 1999; Sporer et al. 2000, 2005; Enting et al. 2000; Bragg et al. 2000;
Liuzzi et al. 2000; Pemberton and Brew 2001; Sabri et al. 2001; Towfighi et al. 2004) as
well as unidentified factors which may contribute to neuropathogenesis (Giulian et al. 1996;
Meeker et al. 1999; Turchan et al. 2003). Factors in the CSF that have shown a significant
correlation with dementia include monocyte chemotactic protein-1 (MCP-1) (Conant et al.
1998; Cinque et al. 1998), urokinase-type plasminogen activator receptor (uPAR) (Sporer et
al. 2005), quinolinate (Heyes et al. 1991), and correlates of damage such as neurofilament
light chain proteins (Hagberg et al. 2000; Gisslen et al. 2007), lipid metabolites (Bandaru et
al. 2007), and beta amyloid/Tau (Brew et al. 2005). Although progress is being made in the
identification of disease markers, we still know very little about the processes that give rise
to neuropathogenesis.
In vitro studies have identified many factors that could contribute to HIV-associated CNS
dysfunction. The many pathogenic pathways that have been proposed highlight the
complexity of the disease processes and emphasize the need to examine a broad range of
markers that reflect the dynamic nature of the disease process including both toxic and
protective functions (Bazan et al. 2005; Streit 2005; Turrin and Rivest 2006). Since studies
often focus on a few inflammatory cytokines, we currently have an incomplete picture of the
interactions of HIV with the CNS that collectively determine the extent of the dysfunction.
In order to better appreciate the nature of these interactions, we used antibody-based arrays
to examine the profile of 120 cytokines, chemokines, and growth factors in human CSF.
These initial studies provide the first comprehensive view of inflammatory, anti-
inflammatory, and neuroprotective proteins in both normal and HIV-1-infected CNS in an
effort to begin to understand the complex changes in HIV-infected brain.
Materials and methods
Human CSF
Twenty HIV+ CSF samples collected from ten clinically characterized individuals with
composite neurological scores ranging from 2 to 176 (see below) were used to evaluate
protein profiles across a range of CNS disease. The study was done with IRB approval from
the University of North Carolina, and all subjects gave informed consent before
participating. Patients were pre-screened for the presence of opportunistic infections and
were excluded from the study if any were present. The CSF samples were chosen to
represent a wide range of clinical profiles including three patients that showed large
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decreases in cognitive function (mean composite neurological scores increased from 41 to
139), two patients that improved substantially (mean composite neurological scores
decreased from 168 to 50), and five patients with moderate or minimal changes. The
intention was to provide the best opportunity to correlate protein values across a wide range
of cognitive disease including changes in cognitive status in a relatively small group of
samples. Sixteen samples of control CSF collected from HIV-negative individuals with no
dementing disease or related inflammation were used to define the normal constituents of
CSF. This control group had a mean age (±SD) of 44.9±15.6 years and was composed of
nine females and seven males. Most patients were under evaluation for lower back pain,
degenerative disks, and peripheral muscle weakness. Symptoms in these patients included
paresthesias, migraine, hydrocephalus, occipital neuralgia, and gait instability. Patients with
any cognitive dysfunction or fever were excluded. Because HIV+ CSF samples were chosen
based on changes in their neurological presentation, they were not specifically matched to
the control group. The mean age of these patients was 39.2 years with seven males and three
females. The CSF used on the protein arrays was collected between October of 2000 and
February of 2004, centrifuged to remove cells, and stored in 250–500-μl aliquots at −80°C
until assayed.
Neurological score
Assessment of HIV-infected patients was accomplished using the AIDS Clinical Trials
Group full neurological evaluation developed by Price and Sidtis (1990). This contains a
global assessment of HIV-associated dementia (HAD, AIDS Dementia Complex) stage
varying from equivocal (0.5) to severe (3.0). In addition, a quantitative scoring procedure for
the neurological evaluation was implemented, increasing the sensitivity of the instrument
and providing domains of functioning (Robertson et al. 2004). This procedure provided a
weighted score approach to the items of the neurological exam and yielded an overall
neurological total score as well as scores for the domains of cognitive, frontal, pyramidal,
extrapyramidal, cranial nerves, cerebellar, spinal, autonomic, and sensory/peripheral. The
total score for neurologically normal controls is typically under 20 with a mean of 5.85
(SD=7.95). Scores around 100 represent mild dementia. Using a cutoff of 59 for the total
neurological score, significant cognitive–motor deficits were detected with a sensitivity of
95% and specificity of 95%, with false positives at 4.8%.
Measurement of CSF toxicity
The presence of putative neurotoxins in CSF was assessed by adding 12.5 μl CSF to cultured
rat forebrain neurons in a 48-well plate to a final volume of 200 μl as previously described
(Meeker et al. 1999). After 24 h, the number of dead cells was quantified by adding 1 μM
ethidium homodimer to the live cultures for a period of 40 min. Dead cell nuclei show bright
red fluorescence with a high signal to noise for semiautomated image analysis using digital
microscopy and Metamorph® imaging software (Molecular Devices, Inc). Cell death was
corrected for basal cell death in the cultures and then normalized to the cell death in cultures
treated with an artificial CSF as the percent increase in cell death. This normalization
corrected for any run to run differences in background cell death which typically ranged
from 2% to 4% of the total number of neurons. Toxicity data were collected on CSF samples
at or near the time of collection and the data archived for future use. Data presented here
represent the net accumulation of these data.
Protein macroarrays
Antibody arrays were purchased from RayBiotech. The protein array protocol was the same
as provided in the RayBiotech C Series 1000 kit User Manual with the exception of an
additional wash step after HRP-streptavidin which was used to further reduce background.
Membranes were blocked for 30 min in serum-based blocking buffer then incubated in 1.0
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ml of human CSF overnight (18 h). They were then washed five times using two separate
wash buffers. After washing, the membranes were incubated in a biotin-conjugated antibody
solution for 2 h. Membranes were again washed, as described above, and incubated in a
solution containing HRP-conjugated streptavidin for 2 h. After incubation, the membranes
were washed once more and incubated in detection buffer for 2 min. The membranes were
exposed to Kodak Bio-Max X-ray film for 2 to 5 s, and kept at −20°C for future reference.
Membranes were developed, digitized, and then analyzed by measuring the optical density
(OD) of each spot using Metamorph image analysis software (Molecular Devices, Inc).
Protein abbreviations are the same as used by RayBiotech and are summarized in Table 1.
Analysis of proteins in CSF
Overall, there was moderate variation in the intensity of signal (OD) reflecting protein
content between different CSF samples and across different runs. This variability was
partially controlled by correcting for film background and normalizing expression to the
total optical density of all spots on the array (relative OD). With this normalization,
relatively consistent expression patterns were seen across patients with an average standard
error of ±18.4% of the OD signal for any given protein. Thus, in most cases, approximately
a 50% change in expression could reliably be detected in the HIV+ samples relative to
normal CSF. By normalizing the data to a total OD value, the assay is not sensitive to
uniform changes in protein expression such as global increases or decreases in most
proteins. However, no such trends were seen in the raw data indicating that the
normalization procedure should provide optimal control of inter-run variability. Negative
controls consisting of a protein-free artificial CSF were also run to determine the non-
specific background activity for each spot on the array. These negative controls were used to
establish minimum baseline values for the array and were subtracted from the positive
signals prior to normalization to provide an accurate estimate of protein expression.
Analysis of changes in CSF proteins
Changes in the expression of individual proteins were evaluated using a t test comparing the
HIV-infected CSF to the uninfected controls. To provide sufficient stringency, proteins with
a p value ≤0.01 were considered significant. Samples were also stratified into three groups
reflecting minimal (neuro score=14.0±5.3, n=5), moderate (neuro score=45.4±2.9, n=10),
and severe (neuro score=150.4± 12.0, n=5) neurological symptoms. A one-way ANOVA on
the stratified data verified the changes seen with the t test but provided little additional
information and less stringency. Thus, only the results from the t test are reported.
To provide greater sensitivity and disease specificity, correlations between the neurological
scores and protein for each CSF sample were performed to determine if trends could be
identified where changes in protein expression might track with cognitive status within the
HIV-infected group. The GraphPad Prism software was used to calculate a correlation
coefficient and level of significance for the regression of relative protein OD onto neuro
score. Correlations with a p value less than 0.05 are reported as significant. Because the use
of the arrays provides a highly detailed look at protein expression in a limited number of
samples (sacrificing power for protein coverage), we also identified proteins which showed
promising trends as having correlations with p values between 0.1 and 0.05.
Results
Pre- and post-highly active antiretroviral therapy toxicity of HIV+ CSF
In 1999, we reported the presence of neurotoxic activity in a subset of CSF samples
collected from HIV-infected patients prior to the introduction of highly active antiretroviral
therapy (HAART) (Meeker et al. 1999). In subsequent years following the introduction of
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HAART, the profile of toxicity in CSF began to change and we found it increasingly
difficult to identify CSF samples with significant toxicity. Figure 1 illustrates changes in the
toxicity profile of 40 HIV+ CSF samples collected from patients prior to the introduction of
HAART and 136 HIV+ CSF samples collected after the introduction of HAART. Control
CSF from HIV-negative individuals was used to establish the 95% confidence limit for
uninfected individuals (dashed lines). After the introduction of HAART, there was a
significant decrease in the relative toxicity of the CSF (p< 0.0001). The percentage of
samples with toxic activity decreased from 47.5% to 8.1%. An unexpected finding was the
extension of the distribution of values from the post-HAART samples into a range where
there was less cell death (apparent neuroprotection). Two of the 40 pre-HAART CSF
samples (5%) fell below the lower cutoff (the percentage expected by chance based on the
95% confidence limit), whereas 23.5% of the post-HAART CSF values fell below the
cutoff. Although there are many factors that could contribute to these differences, we
pursued the possibility that the post-HAART CSF may have neuroprotective as well as toxic
activity with the net effect depending on the relative balance of each. To gain a better
appreciation for the different types of proteins in HIV-infected CNS, we selected 20 HIV+
CSF samples representing a wide range of neurological disease for a broad analysis of 120
cytokines, chemokines, and growth factors. The limited availability of sufficient pre-
HAART CSF required that samples come from patients after the introduction of HAART.
Given the global nature of the screen, samples were selected to reflect a wide range of
neurological disease in the hope of finding trends associated with disease progression with
the understanding that this would reduce our ability to accurately identify changes in
specific proteins.
Normal cytokine, chemokine, and growth factor protein profiles in human CSF
To establish basal parameters for expression of each protein, 16 CSF samples from HIV-
negative individuals were run on the RayBiotech human cytokine protein array VI and VII.
An example of signals seen on the array is illustrated in Fig. 2. Mean OD values for HIV-
negative control CSF for all proteins is summarized in Table 1. The heterogeneity of protein
expression in the control samples was assessed to evaluate normal variation in the CSF
composition. Standard error values ranged from 9.3% to 29.4% of the mean OD for 93% of
the proteins indicating a relatively consistent level of expression in neurologically normal
patients. The remaining 7% of the protein ODs had standard error values ranging from
30.4% to 71.6% indicative of more variation for these eight proteins. A test for normality
indicated that the distribution of OD values for 118 proteins was consistent with a single
normally distributed population (exceptions, fibroblast growth factor-4 and growth-related
oncogene) verifying that the protein expression in the control samples was relatively
homogeneous.
Proteins with significant concentrations in CSF are illustrated in Fig. 3. After correction for
background and non-specific signals from array blanks, 50 proteins were found to be
reliably expressed in the CSF (significantly above zero) using a 99.9% confidence limit
(p<0.001). The mean OD and standard error for each protein is shown for 8 proteins highly
expressed (Fig. 3a), 15 proteins expressed at moderate levels (Fig. 3b), and 27 proteins with
lower expression (Fig. 3c). Variation was low and sensitivity was high with signals
representing as little as 0.012 OD units reliably detected on the array. Negative controls
included with the array had an average optical density of 0.00086±0.00191 giving a 14-fold
signal to noise ratio on the membrane for the lowest signal considered to be statistically
reliable (p<0.001). Notable among the eight proteins with the strongest signals were MCP-1
and tissue inhibitor of metalloproteinase (TIMP) 1 and 2. Other highly expressed proteins
included granulocyte colony-stimulating factor (GCSF), adiponectin (Acrp30), soluble
tumor necrosis factor (TNF) receptor-1 (sTNF RI), uPAR, and insulin-like growth factor
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binding protein-2 (IGFBP-2). Moderately high levels (OD=0.270–0.443, Fig. 3b) of
angiogenin, sgp130, IL-6, and IGFBP-6 were seen. More modest levels (OD=0.111–0.187)
of 11 additional proteins were seen (IL-1ra, sTNF RII, osteoprotegrin, IL-3, fractalkine,
IL-8, EGF, monocyte inflammatory protein (MIP)-1b, MIP-1d, IL-1 R4/ST2, and
macrophage-derived chemokine). Twenty-seven proteins had a low level of expression (Fig.
3c).
Most classical inflammatory (INF-g, TNF-a, IL-1a, IL-1b, IL-12) and anti-inflammatory
proteins (IL-10, IL-13, IL-4 and TGF-b1) were typically expressed at very low or negligible
levels in the control CSF. However, given the high level of stringency, the lack of a
significant signal should be interpreted cautiously. It does not mean that the protein is absent
from CSF, merely that it was not detected with high reliability in this assay.
Effects of HIV infection on CSF proteins
Twenty CSF samples from HIV-infected patients representing different stages of
neurological involvement were analyzed and compared to the profile of normal CSF
described above. For the initial analysis, the overall impact of HIV infection was evaluated
by pooling all HIV+ CSF samples and then comparing the mean level of expression of each
protein to HIV-negative CSF. A significance level of 0.01 was used for each pairwise
comparison to minimize false positives while allowing a relatively sensitive screen of
protein changes associated with HIV infection. With this criterion, 26 proteins increased and
9 proteins decreased relative to the profile seen in HIV-negative control CSF samples. A
summary of the proteins that increased is shown in Fig. 4. The proteins are rank-ordered
based on the magnitude of the increase seen. Several pro-inflammatory proteins were
increased including INF-g and TNF-a, as well as chemokines that might promote immune
cell trafficking (eotaxin-2, C-C motif chemokine 28 (CCL-28), B cell lymphocyte
chemoattractant, granulocyte chemoattractant protein-2, and cutaneous T cell attracting
chemokine). While these changes are consistent with the presence of inflammatory activity,
many increases were also seen in proteins that could be considered anti-inflammatory or
neuroprotective. These proteins included glial-derived neurotrophic factor (GDNF), bone
morphogenic proteins-4 and -6 (BMP-4, BMP-6), brain-derived neurotrophic factor
(BDNF), basic fibroblast growth factor (bFGF), fibroblast growth factor-7 (FGF-7),
granulocyte-macrophage colony-stimulating factor (GM-CSF), vascular endothelium growth
factor (VEGF), and IL-13. Many other proteins were increased although the potential role of
these in CSF is less clear.
In addition to the significant increases summarized above, five additional proteins are worth
noting due to the magnitude of the increases seen. In each case, greater than a 3-fold
increase was seen relative to controls although the results were more variable. These
proteins are insulin-like growth factor-I (IGF-I, 5.1-fold, p=0.0245), IGF binding protein-4
(IGFBP-4, 3.2-fold, p=0.0344) TNF-b (3.3-fold, p=0.0783), agouti-related protein (AgRP,
5.5-fold, p=0.1080), and IL-10 (4.5-fold, p=0.0453).
The nine proteins which decreased in HIV-infected individuals are summarized in Fig. 5.
Notably, three of these proteins were among those with the highest expression in normal
CSF: GCSF, uPAR, and sTNF RI. Smaller decreases were seen in FGF-6, eotaxin-3, IL-3,
fractalkine, IL-1 R4/ST2, and MIP-3 alpha.
Relating changes in CSF protein content to HIV-associated neurological disease
To determine the extent to which changes in the protein profile in CSF were due to infection
alone, we first asked if HIV-positive patients with minimal neurological disease differed
from uninfected individuals. CSF samples from patients with neurological scores less than
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30 (mean ± SEM neurological score=14.0±5.3; n=5) were compared to controls by t test.
Using a cutoff of p≤0.01, a total of 11 proteins changed significantly in the HIV-infected
individuals with little or no neurological symptoms indicating that HIV infection alone had a
significant impact on the protein composition of the CSF. An additional 27 proteins were
just above the cutoff (0.01<p<0.05), suggesting the potential for individual changes in a
diverse array of proteins. These changes are summarized in Table 2 (increases) and Table 3
(decreases). Increases included the anti-inflammatory cytokine, IL-13, as well as the
neuroprotective growth factors BMP-6 and GM-CSF. Decreases were seen in proteins with
endogenous high content and included MCP-1, GCSF, Acrp30, sTNF RI, and uPAR.
The above analyses provided a picture of the general changes in CSF associated with HIV
infection but did not indicate how a given factor might be related to neuropathogenesis. We
evaluated the strength of the relationship between each protein and disease severity by
calculating the correlation between protein content and the matched neurological score. A
significant relationship between neurological score and protein was found for six proteins
illustrated in Figs. 6, 7, and 8.
Two cytokines (IL-5 and IL-6), illustrated in Fig. 6, showed declines with disease severity
with correlations of 0.444 (IL-5) and 0.443 (IL-6), each with a p value of 0.050. The
decrease in IL-6 was paralleled by a decreasing trend in IL-6R (r=0.403, p=0.078, not
shown). Similar trends were also seen for the cytokines IL-4, IL-13, and IL-17 that just fell
short of significance (r=0.393, p=0.087; r=0.3942, p= 0.0855; and 0.426, p=0.061,
respectively). The mean level of protein expression for uninfected control CSF is indicated
on each figure by the open box on the Y axis. This value is included to illustrate that CSF
levels of specific proteins may be increased or decreased relative to control levels depending
on the neurological status. This explains why some proteins with positive increases in Fig. 4
show negative correlations with neurological score (increase in HIV-infected patients with
low neuro scores and a decrease with high neuro scores). This also emphasizes the need to
have CSF profiles for both uninfected patients as well as neurologically normal infected
patients to discriminate between the response to the infection versus protein changes
specifically associated with neurological decline.
One chemokine (MCP-2) decreased with disease severity (Fig. 7) (r=0.498, p=0.025) and
one increased with disease severity (MCP-1, r=0.514, p=0.020). The box on the Y axis
shows the average protein in control CSF. Two additional chemokines, CCL-28 and MIP-3a,
showed decreasing trends with neurological impairment (not shown) that just failed to reach
significance (p’s 0.063 and 0.066).
Two growth factors (BDNF and NT-3), illustrated in Fig. 8, also decreased with disease
severity with r values of 0.482 (p=0.031) and 0.480 (p=0.032) for BDNF and NT-3,
respectively. A similar trend was seen for EGF (r=0.431, p= 0.058), soluble EGF receptor
(r=0.474, p=0.035), and CNTF (r=0.421, p=0.065).
A separate analysis examined which proteins in CSF best predicted subsequent neurological
disease progression in the same patient. CSF protein at the first visit was correlated to the
change in neuro score from the first to the second visit. Two patients with high neuro scores
at entry were not included in the analysis. The average neuro score at the first visit was
34.8±7.1 and the average neuro score at the second visit was 70.4±23.0. The average
interval from the first to the second visit was 7.1±0.9 months. Four proteins, illustrated in
Fig. 9, showed a significant correlation to subsequent changes in neuro scores: BDNF (r=
−0.7248, p=0.042), EGF (r=−0.7480, p=0.033), eotaxin-3 (r=−0.7075, p=0.050), and FGF-6
(r=−0.7707, p=0.025). Ten additional proteins showed promising trends: CNTF (p=0.0577),
IL-5 (p=0.0586), HCC-4 (p=0.0750), IL-1RI (p=0.0762), eotaxin (p=0.0773), b-NGF
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(p=0.0845), Fit-3 ligand (p=0.0886), IL-16 (p=0.0937), IL-2 (p=0.0950), and GCSF
(p=0.0953). Overall, growth factors were disproportionately represented in these results.
Typical inflammatory cytokines were not associated with neurological disease progression.
CSF HIV titers also showed a low correlation to the subsequent change in neuro score
(r=0.106, NS).
Discussion
HIV-associated neuronal damage is thought to be mediated in part by soluble factors
secreted by macrophages and microglia. In vivo support for soluble toxins in the CNS comes
from the demonstration that CSF from HIV-infected patients often contains substances that
are toxic to neurons (Meeker et al. 1999, 2005). Our analysis of CSF samples collected after
the introduction of HAART showed less neurotoxicity than pre-HAART samples. This is
consistent with a general decrease in the severity of neurological disease with the
introduction of HAART. However, these studies also identified potential protective activity
in the post-HAART CSF raising the possibility that the CSF may contain a mix of proteins
reflecting both destructive and repair processes. This is consistent with a growing awareness
of the importance of the dual destructive/protective functions of microglia and macrophages
in a variety of diseases (Streit 2005; Turrin and Rivest 2006).
The protein profiles presented in this paper represent an initial attempt to assess the overall
balance of cytokines, chemokines, growth factors, and related substances in the CSF of
normal and HIV-infected individuals. Because the focus was on establishing a broad profile
of protein expression in a small number of samples, these studies have several limitations.
First, it was not feasible to run large numbers of samples that would allow sensitive
comparisons of individual proteins. Results were non-quantitative and required relatively
large amounts of CSF (1 ml). The wide range of protein expression sometimes made it
difficult to assess low and high abundance proteins on the same array, and careful
background correction and blank arrays were necessary to reduce variability. These
limitations, however, were offset by the ability to evaluate expression patterns of a large
number of proteins with various functions. As such, our findings identified unexpected
changes in protein expression including a potential role for changes in neuroprotective
molecules in HIV pathogenesis.
Normal CSF protein profiles
To understand disease-related changes in CSF proteins, we first needed a characterization of
“normal” CSF to establish baseline levels of expression as well as the variation between
individuals. A relatively consistent pattern of protein expression was seen in control CSF
indicating that the intrinsic individual variation was not a limiting factor in the analysis. The
normal profile of cytokines, chemokines, and growth factors in the CSF of uninfected
individuals indicated a strong presence of proteins within specific functional categories.
Among the most highly expressed were proteins that control monocyte entry and
macrophage activity. The monocyte chemokine, MCP-1, was highly expressed as was the
macrophage-stimulating factor, GCSF. The high level of MCP-1 suggested the presence of a
robust endogenous signal for monocyte recruitment. TIMP-1 and TIMP-2 were also
expressed at high levels, suggesting strong control of matrix metalloproteinases, which
remodel the extracellular matrix and help to control cell trafficking. The TIMPs are thought
to be neuroprotective against HIV-associated neural damage (Johnston et al. 2001;
Suryadevara et al. 2003; Leveque et al. 2004) and may balance chemokine actions that favor
recruitment of monocytes. Three additional substances expressed at high levels were sTNF
RI, uPAR, and Acrp30 whose functions in the CNS are not well understood. High sTNF RI
may reflect endogenous control of TNF activity and intrinsic protection from inflammatory
damage (Nawashiro et al. 1997; Barone et al. 1997; Emsley et al. 2007). High sTNF RI
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levels were paralleled by moderately high sgp130 which may serve a similar function for
IL-6 (Padberg et al. 1999; Jostock et al. 2001). Acrp30, also known as adiponectin, has been
linked to the control of energy expenditure via lipid oxidation and glucose uptake, in part,
through the translocation of glucose transporter 4 and sensitization of the insulin receptor
(Berg et al. 2002; Qi et al. 2004). It has been correlated with mortality in chronic heart
failure (Axelsson et al. 2005) and has been suggested as a systemic marker for wasting
(Kistorp et al. 2005). Decreases resulting from HIV infection (Giralt et al. 2006) and an
inverse correlation with body fat suggest a potential role in HIV-associated metabolic
syndrome in HIV-infected adults and children (Tsiodras and Mantzoros 2006; Verkauskiene
et al. 2006). In addition, decreased expression of the associated protein, leptin, in CSF of
HIV-infected men has been linked to poor neuropsychological performance suggesting a
link between proteins that control energy expenditure and neural disease (Huang et al.
2007). The role of uPAR in the CNS is not well understood, but studies have also linked
changes in expression to HIV pathogenesis (Sidenius et al. 2004; Sporer et al. 2005). Pro-
inflammatory and anti-inflammatory cytokines were generally low in uninfected CSF.
Changes in CSF proteins associated with HIV infection reflect both inflammatory and
neuroprotective activity
Overall, the data illustrated that many changes in protein expression may be due simply to
HIV infection, and these changes include alterations in anti-inflammatory and
neuroprotective proteins as well as inflammatory proteins. The array profiles showed
increases in the inflammatory cytokines, INF-g and TNF-a in response to HIV infection as
previously observed. At the same time, the arrays clearly demonstrated that the response to
infection includes increases in the cytokine IL-13 that has anti-inflammatory actions in the
brain (Wong et al. 1997; Szczepanik et al. 2001) as well as a number of growth factors
(GDNF, BMP-6, BDNF, VEGF, GM-CSF, and bFGF) with putative neuroprotective actions
(Novikova et al. 2000; Stadelmann et al. 2002; Yabe et al. 2002; Storkebaum et al. 2004;
Yasuhara et al. 2004; Husson et al. 2005; Kilic et al. 2005; Wu 2005; Gora-Kupilas and
Josko 2005; Wang et al. 2005; Nakagawa et al. 2006; Kilic et al. 2006). The prominent
increase in growth factors suggests the presence of restorative processes during HIV
infection.
Fewer substances decreased in response to HIV infection but included potentially important
proteins such as GCSF, uPAR, and sTNF RI. Increases in soluble uPAR in the CSF have
previously been associated with neurological disease (Sidenius et al. 2004; Sporer et al.
2005). This is in contrast to our studies where an overall decrease in uPAR levels was seen
with HIV infection. GCSF showed the greatest decrease in response to HIV infection, but
little information is available on the potential role of this protein in HIV pathogenesis.
Is there a general pattern of protein changes associated with neurological decline in HIV
infection?
Although there was a general increase in the pro-inflammatory cytokines, INF-g and TNF-a,
there was little indication of a relationship to neurological disease. Two cytokines, IL-5 and
IL-6, decreased in samples from patients with greater neurological disease. A similar
decreasing trend was seen for the cytokines IL-4, IL-13, and IL-17 that just fell short of
significance (r=0.393, p=0.087 and 0.426, p=0.061, respectively). While this might be
indicative of a general loss of cytokine signaling, it is notable that INF-g and TNF-a
remained high or increased with severity of neurological symptoms.
As previously reported, a significant increase in the chemokine, MCP-1, was seen with
neurological decline (Conant et al. 1998; Kelder et al. 1998; Cinque et al. 1998). However, it
is noteworthy that in the CSF samples analyzed in our studies, a decrease in MCP-1 was
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seen in infected patients with minimal neurological disease. Thus, the “increases” in MCP-1
with cognitive impairment may reflect a reversal of the pattern of MCP-1 secretion in
neurologically asymptomatic versus symptomatic patients. This pattern may explain why
some studies have observed decreases in MCP-1 with HIV infection (Enting et al. 2000;
McCoig et al. 2004), while others show a positive correlation between MCP-1 CSF levels
and neurological disease (Conant et al. 1998; Kelder et al. 1998; Cinque et al. 1998).
When proteins were directly correlated to neurological disease, an unexpected pattern
emerged. Growth factors showed the strongest association with neurological decline. Two
growth factors in particular (BDNF and NT-3) decreased in parallel with neurological
decline with similar trends for two additional growth factors. Infected but unimpaired
patients had higher than normal growth factor expression (hence the overall increase for the
HIV group) which then decreased with more severe neurological disease. Further support for
a role of growth factors comes from the correlation of growth factor expression to
subsequent changes in neurological disease status. Only four proteins showed a significant
relationship and three were growth factors (BDNF, EGF, FGF-6). Thus, a low concentration
of these growth factors was predictive of subsequent neurological decline in the same
patient. This would be consistent with the idea that neurological disease may progress, in
part, due to a loss of endogenous neuroprotection. BDNF, in particular, has been shown to
offer protection specifically against viral and gp120-associated neural damage (Mocchetti
and Bachis 2004; Nosheny et al. 2005; Bachis and Mocchetti 2005; Meisner et al. 2008).
Local administration of BDNF has been shown to reverse gp120-induced neurotoxicity both
in vitro (Mocchetti and Bachis 2004; Bachis and Mocchetti 2005) and in vivo (Nosheny et
al. 2007). The therapeutic effects of memantine have been attributed, in part, to an
upregulation of BDNF in brain tissue of SIV-infected macaques (Meisner et al. 2008), and
reversal of macrophage-associated damage in a SCID mouse model has been correlated with
neurotrophin expression (Poluektova et al. 2004). Additional support for an interaction
between BDNF expression and inflammation is found in various models. Decreases in
BDNF expression have been associated with tissue damage in neurogenic inflammation of
the retina (Bronzetti et al. 2007), atopic dermatitis lesions (Groneberg et al. 2007), brains of
mice exposed to LPS (Schnydrig et al. 2007), and in the CSF of HIV-infected patients
(Albrecht et al. 2006). In addition, in elderly patients, low plasma BDNF was found to be a
robust biomarker of all cause mortality risk (Krabbe et al. 2009). The reason for the decline
in BDNF and NT-3 is not known. It may reflect neural dysfunction or reduced production by
other growth factor secreting cells such as microglia/macrophages (Elkabes et al. 1996). In
post-mortem studies of AIDS patients, BDNF immunoreactivity was found to be co-
localized to infiltrating, activated microglia/macrophages, suggesting that these cells may
play a role in protection and repair (Soontornniyomkij et al. 1998). It is possible that altered
functions of these cells may contribute to the loss of growth factor protection.
Overall, the above patterns of protein expression reinforce two important points. First,
although inflammatory proteins were generally elevated, no clear relationship was seen with
disease progression. Second, anti-inflammatory and neuroprotective activity in CSF must be
factored into theories of HIV neuropathogenesis. The loss of growth factors, in particular,
correlated with neurological disease and was best at predicting subsequent neurological
decline. Although the number of samples was too small to draw definitive conclusions, the
findings support a growing number of studies indicating that a loss of growth factor
expression may not only be a useful marker of disease progression but also a potential target
of therapeutic approaches designed to preserve the intrinsic neuroprotective activity in the
CNS. The current observations have set the framework for more comprehensive studies of
proteins released into the CNS in response to disease. The relative stability of the protein
profiles across the control samples indicates that it is feasible to establish norms from which
pathological samples can be judged. More work is needed to establish the functional
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significance of changes in neuroprotective and anti-inflammatory factors in HIV-infected
individuals as well as the therapeutic potential of treatments designed to enhance these
processes.
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Summary of toxic activity in human CSF collected prior to (pre) or after (post) the
introduction of HAART. Toxic activity was assessed by measuring relative changes in cell
death (percent increase in cell death) in rat neural cultures treated with a 1:10 dilution of the
CSF in culture medium as compared to cultures treated with artificial CSF. All stages of
disease were represented in the samples. HIV-negative control CSF was used to define the
normal range of CSF for comparison which was defined as the mean toxicity ±1.96 SD units
(p<0.05, dashed lines). Data points falling above this range were counted as toxic and
represented 47.5% of all pre-HAART CSF samples (n=40). Two values in the pre-HAART
group fell below this range which was expected by chance. Of the 136 CSF samples
analyzed after the introduction of HAART, 8.1% were toxic and 23.5% were below the
cutoff, suggesting protective activity
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Example of the signals obtained on the RayBiotech membrane protein arrays after
incubation in control CSF. The optical density of each spot was measured. Prominent signals
and some proteins of interest are identified on the array
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Summary of the mean ± SEM (n=16) protein expression in CSF from HIV-negative controls
that were significantly above membrane blanks (p<0.01). a Eight proteins were expressed at
very high levels in CSF. b Fifteen proteins were expressed at moderate levels (note the
change in OD scale). c Twenty-seven proteins were expressed at low levels. The standard
error values were generally low indicating good consistency across patients for most
proteins
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Proteins increased in CSF from HIV-infected patients relative to HIV-negative controls.
Bars represent the mean relative OD ± SEM for 20 CSF samples from patients with a wide
range of neurological disease. Twenty-six proteins were significantly increased (t test,
p<0.01) in the HIV+ CSF. Proteins are rank-ordered from greatest to least change
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Proteins decreased in CSF from HIV-infected patients relative to HIV-negative controls.
Bars represent the mean relative OD ± SEM for 20 CSF samples from patients with a wide
range of neurological disease. Nine proteins were significantly decreased (t test, p<0.01) in
the HIV+ CSF. Proteins are rank-ordered from greatest to least change
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Correlation between cytokines in CSF and neurological score (neuro score). A significant
negative relationship was seen between the expression of the cytokines IL-5 and IL-6 and
neurological disease severity. In each case, the open box on the Y axis shows the average
content of each protein in CSF from the HIV-negative controls. Comparison to the control
values illustrates that low neurological scores are associated with cytokine increases and
higher scores with cytokine decreases
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Correlation between chemokines in CSF and neurological score (neuro score). A significant
positive relationship was seen between the expression of the chemokine MCP-1 and
neurological disease severity. MCP-2 showed a significant negative correlation with
neurological score. In each case, the open box on the Y axis shows the average content of
each protein in CSF from the HIV-negative controls
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Correlation between growth factors in CSF and neurological score (neuro score). A
significant negative relationship was seen between the expression of the growth factors
BDNF and NT-3 and neurological disease severity. The open box on the Y axis shows the
average content of each protein in CSF from the HIV-negative controls. In most cases, there
is an increase in growth factor expression in patients with low neurological scores and a
decline as neurological disease severity increases
Meeker et al. Page 23














Correlation between growth factor expression in the CSF (normalized OD) at the first visit
and the change in the neurological score (neuro score) at the second visit. A significant
negative relationship was seen for BDNF, EGF, eotaxin-3, and FGF-6, indicating that low
levels of growth factors (BDNF, EGF, FGF-6) or chemokine (eotaxin-3) predicted a
subsequent decline in neurological status
Meeker et al. Page 24



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































J Neurovirol. Author manuscript; available in PMC 2012 June 1.
